RU2007132981A - Способ лечения и предупреждения потери костной ткани - Google Patents

Способ лечения и предупреждения потери костной ткани Download PDF

Info

Publication number
RU2007132981A
RU2007132981A RU2007132981/15A RU2007132981A RU2007132981A RU 2007132981 A RU2007132981 A RU 2007132981A RU 2007132981/15 A RU2007132981/15 A RU 2007132981/15A RU 2007132981 A RU2007132981 A RU 2007132981A RU 2007132981 A RU2007132981 A RU 2007132981A
Authority
RU
Russia
Prior art keywords
bone
treating
bone tissue
preventing bone
tissue loss
Prior art date
Application number
RU2007132981/15A
Other languages
English (en)
Inventor
Джон Дейвид АЛЛАРД (US)
Джон Дейвид АЛЛАРД
Роберт Фредерик КЛЕЙН (US)
Роберт Фредерик КЛЕЙН
Гэри Аллен ПЕЛТЗ (US)
Гэри Аллен ПЕЛТЗ
Original Assignee
Ф. Хоффманн-Ля Рош Аг (Ch)
Ф. Хоффманн-Ля Рош Аг
Дзе Говернмент Оф Дзе Юнайтед Стейтс (Us)
Дзе Говернмент Оф Дзе Юнайтед Стейтс
Орегон Хелс Энд Сайенс Юниверсити (Us)
Орегон Хелс Энд Сайенс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг (Ch), Ф. Хоффманн-Ля Рош Аг, Дзе Говернмент Оф Дзе Юнайтед Стейтс (Us), Дзе Говернмент Оф Дзе Юнайтед Стейтс, Орегон Хелс Энд Сайенс Юниверсити (Us), Орегон Хелс Энд Сайенс Юниверсити filed Critical Ф. Хоффманн-Ля Рош Аг (Ch)
Publication of RU2007132981A publication Critical patent/RU2007132981A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90241Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/108Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)

Claims (2)

1. Способ диагностики предрасположенности к потере костной ткани у индивидуума, заключающийся в том, что осуществляют выявление полиморфизма гена 15-липоксигеназы индивидуума.
2. Набор для диагностики предрасположенности к потере костной ткани, содержащий по меньшей мере один олигонуклеотид для обнаружения полиморфизма гена 15-липоксигеназы, который связан с потерей костной ткани.
RU2007132981/15A 2002-02-08 2007-09-03 Способ лечения и предупреждения потери костной ткани RU2007132981A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35525502P 2002-02-08 2002-02-08
US60/355,255 2002-02-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2004127131/15A Division RU2319483C2 (ru) 2002-02-08 2003-02-03 Способ лечения и предупреждения потери костной ткани

Publications (1)

Publication Number Publication Date
RU2007132981A true RU2007132981A (ru) 2009-03-10

Family

ID=27734489

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2004127131/15A RU2319483C2 (ru) 2002-02-08 2003-02-03 Способ лечения и предупреждения потери костной ткани
RU2007132977/15A RU2358728C2 (ru) 2002-02-08 2007-09-03 Способ лечения и предупреждения потери костной ткани
RU2007132981/15A RU2007132981A (ru) 2002-02-08 2007-09-03 Способ лечения и предупреждения потери костной ткани

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2004127131/15A RU2319483C2 (ru) 2002-02-08 2003-02-03 Способ лечения и предупреждения потери костной ткани
RU2007132977/15A RU2358728C2 (ru) 2002-02-08 2007-09-03 Способ лечения и предупреждения потери костной ткани

Country Status (15)

Country Link
US (2) US20030175680A1 (ru)
EP (3) EP1666883A1 (ru)
JP (1) JP2005531498A (ru)
KR (2) KR100653017B1 (ru)
CN (3) CN100410388C (ru)
AT (1) ATE385835T1 (ru)
AU (1) AU2003206822C1 (ru)
BR (1) BR0307522A (ru)
CA (2) CA2697599A1 (ru)
DE (1) DE60319156T2 (ru)
ES (1) ES2299923T3 (ru)
MX (1) MXPA04007611A (ru)
PL (1) PL372228A1 (ru)
RU (3) RU2319483C2 (ru)
WO (1) WO2003066048A2 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) * 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
WO2002096284A1 (en) 2001-05-25 2002-12-05 Imaging Therapeutics, Inc. Methods to diagnose treat and prevent bone loss
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US7664298B2 (en) 2003-03-25 2010-02-16 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
WO2005123130A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
CA2580726A1 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
US20070036770A1 (en) * 2005-08-12 2007-02-15 Wagner Darrell O Biologic device for regulation of gene expression and method therefor
WO2007022427A2 (en) 2005-08-18 2007-02-22 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
US20090247634A1 (en) * 2006-06-27 2009-10-01 Hans-Erik Claesson Methods for identifying modulators of eoxin formation
US20080076836A1 (en) * 2006-09-01 2008-03-27 Cardiac Pacemakers, Inc Method and apparatus for using light to enhance cell growth and survival
WO2008034101A2 (en) * 2006-09-15 2008-03-20 Imaging Therapeutics, Inc. Method and system for providing fracture/no fracture classification
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
EP2142924A2 (en) * 2007-04-26 2010-01-13 President And Fellows Of Harvard College Assays for the identification of compounds that modulate bone formation and mineralization
WO2009105723A2 (en) * 2008-02-22 2009-08-27 Accelalox, Inc. Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage
US20110136728A1 (en) * 2009-12-09 2011-06-09 Patricia Grasso Methods of increasing bone formation using leptin-related peptides
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
CN102138961A (zh) * 2010-02-02 2011-08-03 北京绿色金可生物技术股份有限公司 黑豆皮提取物在预防和治疗骨关节炎的产品中的应用
KR101474053B1 (ko) 2011-04-08 2014-12-19 울산대학교 산학협력단 골다공증 또는 골다공성 골절 발생 위험도 예측용 다형성 마커
RU2517037C1 (ru) * 2013-02-08 2014-05-27 Евгений Викторович Ларионов Способ получения костного минерального компонента и костный минеральный компонент для замещения и восстановления дефектов костной ткани
EP3036226B1 (en) 2013-08-22 2020-01-08 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
EP3159003A3 (en) * 2015-10-23 2017-07-19 Universiti Putra Malaysia Composition for enhancing bone growth, preventing bone resorption disorders and for joint health
CN106405064B (zh) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 一种40岁以上女性骨转换率的评估方法
CN108251454A (zh) * 2017-12-26 2018-07-06 温州医科大学附属第医院 一种脂氧合酶基因修饰间充质干细胞的获取方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA838339B (en) * 1982-11-11 1985-06-26 Beecham Group Plc Novel arachidonic acid analogues and pharmaceutical compositions containing them
DE3360677D1 (en) 1982-11-11 1985-10-03 Beecham Group Plc Arachidonic acid analogues, processes for their preparation and their use in medicine
US4623661A (en) * 1985-04-26 1986-11-18 Abbott Laboratories Lipoxygenase inhibiting compounds
US4605669A (en) 1985-04-26 1986-08-12 Abbott Laboratories Lipoxygenase inhibiting naphthohydroxamic acids
US4761403A (en) * 1986-04-09 1988-08-02 Abbott Laboratories Lipoxygenase inhibiting compounds
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
CA2087836A1 (en) * 1990-07-25 1992-01-26 Dee W. Brooks Acetylene derivatives having lipoxygenase inhibitory activity
US5478579A (en) * 1991-02-06 1995-12-26 Biodyn Medical Research, Inc. Method for treatment of osteoporosis
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US5620997A (en) * 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU1529799A (en) 1997-12-23 1999-07-12 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
WO2001096298A2 (en) 2000-06-14 2001-12-20 Warner-Lambert Company 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase

Also Published As

Publication number Publication date
RU2004127131A (ru) 2005-09-20
JP2005531498A (ja) 2005-10-20
CN1936023A (zh) 2007-03-28
WO2003066048A2 (en) 2003-08-14
RU2358728C2 (ru) 2009-06-20
AU2003206822A1 (en) 2003-09-02
RU2319483C2 (ru) 2008-03-20
CN1630518A (zh) 2005-06-22
KR100653017B1 (ko) 2006-12-01
MXPA04007611A (es) 2005-05-27
EP1666883A1 (en) 2006-06-07
EP1476153A2 (en) 2004-11-17
ATE385835T1 (de) 2008-03-15
CN100410388C (zh) 2008-08-13
KR20060029705A (ko) 2006-04-06
DE60319156T2 (de) 2009-01-29
AU2003206822B2 (en) 2008-05-29
CN1287789C (zh) 2006-12-06
RU2007132977A (ru) 2009-03-10
KR20040111353A (ko) 2004-12-31
US20060079488A1 (en) 2006-04-13
EP1634618B1 (en) 2008-02-13
ES2299923T3 (es) 2008-06-01
PL372228A1 (en) 2005-07-11
BR0307522A (pt) 2004-12-07
KR100589819B1 (ko) 2006-06-14
CA2474431A1 (en) 2003-08-14
DE60319156D1 (de) 2008-03-27
EP1634618A1 (en) 2006-03-15
US20030175680A1 (en) 2003-09-18
AU2003206822C1 (en) 2009-01-22
CA2697599A1 (en) 2003-08-14
CN1896270A (zh) 2007-01-17
WO2003066048A3 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
RU2007132981A (ru) Способ лечения и предупреждения потери костной ткани
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
BR0315689A (pt) Alvo para terapia de dano cognitivo
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
EP2065366A3 (en) HIF hydroxylase inhibitors
CY1106915T1 (el) Συνδυασμοι διαχωριστη(ων) χολικου οξεος και αναστολεα(ων) απορροφησης στερολης και θεραπειες για αγγειακες ενδειξεις
DE69930950D1 (de) Zinkfinger-bindungsdomänen für gnn
TW200731984A (en) C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
IL166466A0 (en) Methods for the treatment of dementia based on apoe genotype
GB0606096D0 (en) Screening method
SG159382A1 (en) Effectors of innate immunity
DE60214388D1 (de) Verbindungen, bei denen es sich um wirksame inhibitoren des na+/ca2+ austauschmechanismus handelt und die sich zur behandlung von arrhythmien eignen
WO2006053955A3 (en) Method and kit for detecting a risk of essential arterial hypertension
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE443262T1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
DE10346721A1 (de) Oligonukleotide, diese enthaltende Mittel und deren Verwendung
DE60329929D1 (de) Molekulare identifizierung von bakterien des genus streptococcus und verwandte genus
DE69332375D1 (de) Hundecoronavirus s gen und verwendung davon
WO2007001943A3 (en) Prefoldin 4 in the treatment and diagnosis of cancer
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands
DE60327793D1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
PL1819354T3 (pl) Sposoby i związki do leczenia cukrzycy
ATE332970T1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
WO2005002505A3 (en) Apolipoprotein c-1 induced apoptosis
WO2004052186A3 (en) Expressed genes that define the osteoclast phenotype